Alembic Pharmaceuticals informs about press release

02 Nov 2022 Evaluate

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g. In this regard, the company has enclosed a press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

1044.60 -10.40 (-0.99%)
23-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1340.80
Cipla 1476.45
Lupin 2160.20
Zydus Lifesciences 972.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.